- AU$335.58m
- AU$305.40m
- AU$6.76m
- 59
- 15
- 94
- 59
Annual income statement for Orthocell, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.836 | 1.22 | 1.62 | 5.09 | 6.76 |
| Cost of Revenue | |||||
| Gross Profit | 0.331 | 0.592 | 0.913 | 4.07 | 5.14 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 9.89 | 12.6 | 12.9 | 14.5 | 17 |
| Operating Profit | -9.06 | -11.4 | -11.3 | -9.41 | -10.2 |
| Net Income Before Taxes | -9.06 | -11.4 | -11.3 | -9.41 | -10.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.15 | -9.04 | -9.11 | -6.25 | -7.18 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.15 | -9.04 | -9.11 | -6.25 | -7.18 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.15 | -9.04 | -9.11 | -6.25 | -7.18 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.037 | -0.049 | -0.047 | -0.032 | -0.035 |